A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity

Condition studied

Participants with overweight or obesity

Investigational medicinal product(s)

Eligibility

Primary endpoint

Relative change in body weight from baseline (week 0) to end of treatment (week 26)

Endpoint detail

Number of treatment emergent adverse events (TEAEs) from baseline (week 0) to end of study (week 33), Number of treatment emergent serious adverse events (TESAEs) from baseline (week 0) to end of study (week 33)